<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Screening for Familial Intracranial Aneurysms" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/screening-for-familial-intracranial-aneurysms/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/screening-for-familial-intracranial-aneurysms/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2008-03-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Screening for Familial Intracranial Aneurysms" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-07T07:15:32+00:00","datePublished":"2008-03-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Screening for Familial Intracranial Aneurysms","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/screening-for-familial-intracranial-aneurysms/"},"url":"https://clinicaltree.github.io/posts/screening-for-familial-intracranial-aneurysms/"}</script><title>Screening for Familial Intracranial Aneurysms | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Screening for Familial Intracranial Aneurysms</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Screening for Familial Intracranial Aneurysms</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1206982800" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Mar 31, 2008 </em> </span> <span> Updated <em class="" data-ts="1680851732" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 7, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Hidemasa Takao MD</a> </em>, <em> <a href="">Takeshi Nojo MD MPH</a> </em>, <em> <a href="">Kuni Ohtomo MD DMSc</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2324 words"> <em>12 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>To evaluate the potential benefits, harms, and cost-effectiveness of screening for asymptomatic, unruptured intracranial aneurysms in family members of patients with aneurysmal subarachnoid hemorrhage (SAH).</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Using a Markov model, we performed a decision and cost-effectiveness analysis comparing magnetic resonance (MR) angiography screening for asymptomatic, unruptured intracranial aneurysms to no screening in family members of patients with aneurysmal SAH. Treatment of unruptured intracranial aneurysms was determined according to patient age and aneurysm size and location. Cohort age was taken as 40 years.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>In family members with two or more affected first-degree relatives, screening compared with no screening had an incremental cost-effectiveness ratio (ICER) of $37,400 per quality-adjusted life-year (QALY). With screening, life expectancy increased from 39.44 years to 39.55 years. The ICER of screening was &gt;$50,000 per QALY if age at screening was ≥50 years. In family members with one affected first-degree relative, screening compared with no screening had an ICER of $56,500 per QALY.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The results suggest that MR angiography screening for asymptomatic, unruptured intracranial aneurysms in family members with two or more affected first-degree relatives is cost-effective. The benefit and cost-effectiveness are dependent on age at screening.</p><p>Unruptured intracranial aneurysms affects up to 2%–4% of the population ( ). Family members with one or more first-degree relatives with aneurysmal subarachnoid hemorrhage (SAH) have a higher relative risk of harboring an unruptured intracranial aneurysm than the general population ( ). In family members with only one affected first-degree relative, the risk of harboring an unruptured intracranial aneurysm is approximately 4%. Family members with two or more affected first-degree relatives have an approximately 8% risk of harboring an unruptured intracranial aneurysm. The management of patients with unruptured intracranial aneurysms depends on the natural history of these lesions and on morbidity and mortality rates associated with their repair. In 2003, the International Study of Unruptured Intracranial Aneurysms (ISUIA) investigators reported prospective data on the natural history and treatment outcomes of unruptured intracranial aneurysms ( ). Aneurysm rupture rates varied depending on aneurysm size and location and treatment outcomes depended on patient age and aneurysm size and location ( ).</p><p>Recommendations regarding screening for asymptomatic, unruptured intracranial aneurysms in family members with one or more affected first-degree relatives are controversial ( ). In 2000, a task force of the Stroke Council of the American Heart Association published recommendations for the management of patients with an unruptured intracranial aneurysm ( ). They concluded that screening in these populations should be considered on an individual basis. Previous decision analyses ( ) showed that there was no benefit of screening for asymptomatic, unruptured intracranial aneurysms in these populations with the assumption that all detected aneurysms were surgically treated. Treatment of unruptured intracranial aneurysms should be determined based on the natural history of these lesions and on morbidity and mortality rates associated with their repair. The purpose of our study was to evaluate the potential benefits, harms, and cost-effectiveness of screening for asymptomatic, unruptured intracranial aneurysms in family members of patients with aneurysmal SAH, incorporating the results of the prospective ISUIA ( ).</p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="study-design"><span class="mr-2">Study Design</span><a href="#study-design" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ScreeningforFamilialIntracranialAneurysms/0_1s20S1076633207006836.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ScreeningforFamilialIntracranialAneurysms/0_1s20S1076633207006836.jpg" alt="Figure 1, Simplified schematic of the decision tree. Squares: decisions; circles: chance events; M: Markov cycle trees (M1, no aneurysm; M2, no treatment; M3, surgery; M4, endovascular treatment); MRA: magnetic resonance angiography; DSA: digital subtraction angiography." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Probabilities, Costs, and Utilities</p><p>Baseline Range Source Age, y 40 30–70 ⁎ Sex Male/Female CDC, 2003 ( ) Probabilities Unruptured intracranial aneurysms Prevalence Meta-analysis ( ) Family members with one affected first-degree relative 4.0% 2.6%–5.8% † Family members with two or more affected first-degree relatives 8.0% 3.9%–14% † Site distribution Meta-analysis ( ) Cavernous carotid artery 8.3% 7.5%–9.2% † ISUIA, 2003 ( ) Anterior circulation 82% 78%–85% † Posterior circulation 10% 7.7%–13% † Size distribution Meta-analysis ( ) &lt;7 mm 72% 68%–77% † 7–12 mm 21% 17%–25% † 13–24 mm 6.5% 4.1%–9.5% † ≥25 mm 0.8% 0.09%–2.8% † MRA Meta-analysis ( ) Sensitivity, &lt;7 mm 92% 88%–96% † ≥7 mm 99% 93%–100% † Specificity 95% 91%–97% † Angiography Meta-analysis ( ) Disability 0.07% 0.01%–0.21% † Aneurysm rupture rates (per year),% ISUIA, 2003 ( ) Cavernous carotid artery &lt;7 mm 0 — 7–12 mm 0 — 13–24 mm 0.6 0.1–2.0 † ≥25 mm 1.3 0.1–5.3 † Anterior communicating or anterior cerebral artery/middle cerebral artery/internal carotid artery &lt;7 mm 0 — 7–12 mm 0.5 0.3–0.9 † 13–24 mm 3.1 2.1–4.4 † ≥25 mm 9.7 6.9–13.3 † Posterior circulation/posterior communicating artery &lt;7 mm 0.5 0.2–1.0 † 7–12 mm 3.1 2.0–4.5 † 13–24 mm 4.0 2.4–6.2 † ≥25 mm 12.9 8.5–18.7 † Background mortality US age/sex specific CDC, 2002 ( ) Relative risks of mortality No disability after SAH Cohort study ( ) Age, 4–39 6.3 4.4–9.0 † Age, 40–54 2.4 1.8–3.2 † Age, &gt;55 1.3 1.0–1.7 † Disability after SAH Cohort study ( ) Age, 4–44 8.7 7.1–10.6 † Age, 45–54 5.4 4.5–6.5 † Age, &gt;55 3.4 2.9–3.8 † Disability from cerebral angiography or treatment of unruptured aneurysms 2.0 1.5–2.5 † Cohort study ( ) SAH Case fatality 0.50 0.32–0.67 Meta-analysis ( ) Case disability 0.15 0.10–0.20 Meta-analysis ( ) Rate of cognitive impairment 50% 41%–58% Cohort study ( ) Surgery ISUIA, 2003 ( ) Poor outcome rates Anterior circulation &lt;13 mm (age &lt;50) 0.06 0.04–0.08 † (age ≥50) 0.12 0.09–0.15 † 13–24 mm (age &lt;50) 0.04 0.02–0.09 † (age ≥50) 0.25 0.19–0.31 † ≥25 mm (age &lt;50) 0.23 0.09–0.44 † (age ≥50) 0.32 0.22–0.44 † Posterior circulation &lt;13 mm (age &lt;50) 0.12 0.05–0.21 † (age ≥50) 0.13 0.06–0.22 † 13–24 mm (age &lt;50) 0.29 0.11–0.54 † (age ≥50) 0.43 0.28–0.60 † ≥25 mm (age &lt;50) 0.44 0.30–0.60 † (age ≥50) — — Poor outcome Death 19% 18%–21% Disability 11% 9%–12% Cognitive impairment 47% 45%–49% Disability with cognitive impairment 23% 21%–25% Posttreatment annual rupture rate 0% Estimate ( ) Endovascular treatment ISUIA, 2003 ( ) Poor outcome rates Anterior circulation &lt;13 mm (age &lt;50) 0.07 0.03–0.15 † (age ≥50) 0.07 0.03–0.12 † 13–24 mm (age &lt;50) 0.05 0.01–0.15 † (age ≥50) 0.08 0.04–0.15 † ≥25 mm (age &lt;50) 0.16 0.03–0.43 † (age ≥50) 0.13 0.06–0.25 † Posterior circulation &lt;13 mm (age &lt;50) 0.11 0.03–0.28 † (age ≥50) 0.08 0.02–0.19 † 13–24 mm (age &lt;50) 0.17 0.01–0.59 † (age ≥50) 0.23 0.10–0.42 † ≥25 mm (age &lt;50) — — (age ≥50) 0.40 0.23–0.60 † Poor outcome Death 33% 28%–37% Disability 9% 7%–12% Cognitive impairment 37% 33%–42% Disability with cognitive impairment 21% 17%–25% Posttreatment relative risk of rupture 0.39 0.28–0.49 ‡ Estimate ( ) Posttreatment annual rupture rate Rupture rate × relative risk of rupture Estimate ( ) Costs, $ MRA 560 390–770 † ‡ Medicare ( ) Angiography 1,400 1,000–2,000 † ‡ Medicare ( ) Surgery 30,000 21,000–42,000 † ‡ Cohort study ( ) Endovascular treatment 25,000 17,000–34,000 † ‡ Cohort study ( ) SAH 59,000 42,000–82,000 † ‡ Cohort study ( ) Disability (annual) 25,000 18,000–35,000 † ‡ Cohort study ( ) Utilities Disability 0.26 0.11–0.39 Meta-analysis ( ) Quality reduction Cognitive impairment 50% 30%–70% ‡ Estimate ( ) Treatment of unruptured aneurysms (3 months) 75% 0%–100% ⁎ ‡ Estimate ( ) SAH (3 months) 0% 0%–100% ⁎ ‡ Estimate ( ) Knowingly living with unruptured aneurysm 0.95 § 0.90–1.00 ‡ Estimate ( )</p><p>ISUIA: International Study of Unruptured Intracranial Aneurysms; CDC: Centers for Disease Control and Prevention; MRA: magnetic resonance angiography; SAH: subarachnoid hemorrhage.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="the-markov-model-and-its-transition-probabilities"><span class="mr-2">The Markov Model and Its Transition Probabilities</span><a href="#the-markov-model-and-its-transition-probabilities" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="costs"><span class="mr-2">Costs</span><a href="#costs" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="quality-of-life"><span class="mr-2">Quality of Life</span><a href="#quality-of-life" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="outcome-measures"><span class="mr-2">Outcome Measures</span><a href="#outcome-measures" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="analyses"><span class="mr-2">Analyses</span><a href="#analyses" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="base-case-analysis"><span class="mr-2">Base-Case Analysis</span><a href="#base-case-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 2</p><p>Effectiveness, Cost, and Cost-effectiveness Compared with No Screening (40-Year-Old Cohorts)</p><p>QALYs Cost, $ Incremental cost per QALY, $ Average Incremental Average Incremental Family members with two or more affected first-degree relatives (base case) No screening 22.40 590 Screening 22.43 0.04 1,900 1,300 37,400 Family members with one affected first-degree relative No screening 22.44 290 Screening 22.45 0.02 1,300 1,000 56,500</p><p>QALY: quality-adjusted life-year.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="sensitivity-analyses"><span class="mr-2">Sensitivity Analyses</span><a href="#sensitivity-analyses" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ScreeningforFamilialIntracranialAneurysms/1_1s20S1076633207006836.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ScreeningforFamilialIntracranialAneurysms/1_1s20S1076633207006836.jpg" alt="Figure 2, Cost-effectiveness acceptability curves. (a) Family members with two or more first-degree relatives with subarachnoid hemorrhage. (b) Family members with one affected first-degree relative. Each line shows the proportion of simulations for which that strategy would be optimal for each willingness-to-pay value ($per quality-adjusted life-year) ( 28 29 30 )." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Rinkel G.J.E., Djibuti M., Algra A., et. al.: Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke 1998; 29: pp. 251-256.</p><li><p>2. Rinkel G.J.E.: Intracranial aneurysm screening: indications and advice for practice. Lancet Neurol 2005; 4: pp. 122-128.</p><li><p>3. International Study of Unruptured Intracranial Aneurysms Investigators: Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362: pp. 103-110.</p><li><p>4. Bederson J.B., Awad I.A., Wiebers D.O., et. al.: Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2000; 31: pp. 2742-2750.</p><li><p>5. Crawley F., Clifton A., Brown M.M.: Should we screen for familial intracranial aneurysm?. Stroke 1999; 30: pp. 312-316.</p><li><p>6. The Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group: Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. N Engl J Med 1999; 341: pp. 1344-1350.</p><li><p>7. Doubilet P., Begg C.B., Weinstein M.C., et. al.: Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5: pp. 157-177.</p><li><p>8. Takao H., Nojo T.: Treatment of unruptured intracranial aneurysms: decision and cost-effectiveness analysis. Radiology 2007; 244: pp. 755-766.</p><li><p>9. White P.M., Wardlaw J.M., Easton V.: Can noninvasive imaging accurately depict intracranial aneurysms?. Radiology 2000; 217: pp. 361-370.</p><li><p>10. Cloft H.J., Joseph G.J., Dion J.E.: Risk of cerebral angiography in patients with subarachnoid hemorrhage, cerebral aneurysm, and arteriovenous malformation: a meta-analysis. Stroke 1999; 30: pp. 317-320.</p><li><p>11. Vindlacheruvu R.R., Mendelow A.D., Mitchell P.: Risk-benefit analysis of the treatment of unruptured intracranial aneurysms. J Neurol Neurosurg Psychiatry 2005; 76: pp. 234-239.</p><li><p>12. Mitchell P., Gholkar A., Vindlacheruvu R.R., et. al.: Unruptured intracranial aneurysms: benign curiosity or ticking bomb?. Lancet Neurol 2004; 3: pp. 85-92.</p><li><p>13. US Department of Health and Human Services, Centers for Disease Control and Prevention: http://www.cdc.gov Accessed February 15, 2006</p><li><p>14. Johnston S.C., Gress D.R., Kahn J.G.: Which unruptured cerebral aneurysms should be treated?. Neurology 1999; 52: pp. 1806-1815.</p><li><p>15. Hop J.W., Rinkel G.J.E., Algra A., et. al.: Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systemic review. Stroke 1997; 28: pp. 660-664.</p><li><p>16. Mayer S.A., Kreiter K.T., Copeland D., et. al.: Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology 2002; 59: pp. 1750-1758.</p><li><p>17. Kreiter K.T., Copeland D., Bernardini G.L., et. al.: Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke 2002; 33: pp. 200-209.</p><li><p>18. Ronkainen A., Niskanen M., Rinne J., et. al.: Evidence for excess long-term mortality after treated subarachnoid hemorrhage. Stroke 2001; 32: pp. 2850-2853.</p><li><p>19. Strauss D.J., Shavelle R.M., Anderson T.W.: Long-term survival of children and adolescents after traumatic brain injury. Arch Phys Med Rehabil 1998; 79: pp. 1095-1100.</p><li><p>20. Wiebers D.O.: Patients with small, asymptomatic, unruptured intracranial aneurysms and no history of subarachnoid hemorrhage should generally be treated conservatively. Stroke 2005; 36: pp. 408-409.</p><li><p>21. Post P.N., Kievit J., van Baalen J.M., et. al.: Routine duplex surveillance does not improve the outcome after carotid endarterectomy: a decision and cost utility analysis. Stroke 2002; 33: pp. 749-755.</p><li><p>22. Gage B.F., Cardinalli A.B., Albers G.W., et. al.: Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: pp. 1839-1845.</p><li><p>23. US Department of Labor, Bureau of Labor Statistics: http://www.bls.gov Accessed March 6, 2006</p><li><p>24. Huang J.: van Gelder JM. Neurosurgery 2002; 51: pp. 1101-1107.</p><li><p>25. Post P.N., Stiggelbout A.M., Wakker P.P.: The utility of health states after stroke: a systematic review of the literature. Stroke 2001; 32: pp. 1425-1429.</p><li><p>26. Aoki N., Beck J.R., Kitahare T., et. al.: Reanalysis of unruptured intracranial aneurysm management: effect of a new international study on the threshold probabilities. Med Decis Making 2001; 21;: pp. 87-96.</p><li><p>27. King J.T., Glick H.A., Mason T.J., et. al.: Elective surgery for asymptomatic, unruptured, intracranial aneurysms: a cost-effectiveness analysis. J Neurosurg 1995; 83: pp. 403-412.</p><li><p>28. Hunink M.G.M., Glasziou P.P., Siegel J.E., et. al.: Decision making in health and medicine: integrating evidence and values.2001.Cambridge University PressCambridge</p><li><p>29. Gold M.R., Siegel J.E., Russell L.B., et. al.: Cost-effectiveness in health and medicine.1996.Oxford University PressNew York</p><li><p>30. Drummond M.F., Sculpher M.J., Torrance G.W., et. al.: Methods for the economic evaluation of health care programmes.2005.Oxford University PressNew York</p><li><p>31. TreeAge Pro 2006 user’s manual.2006.TreeAge Software, IncWilliamstown, MA</p><li><p>32. Yoshimoto Y., Wakai S.: Cost-effectiveness analysis of screening for asymptomatic, unruptured intracranial aneurysms: a mathematical model. Stroke 1999; 30: pp. 1621-1627.</p><li><p>33. Butler W.E., Barker F.G., Crowell R.M.: Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracranial aneurysms: a decision analysis. Neurosurgery 1996; 38: pp. 506-516.</p><li><p>34. Wermer M.J.H., Buskens E., van der Schaaf I.C., et. al.: Yield of screening for new aneurysms after treatment for subarachnoid hemorrhage. Neurology 2004; 62: pp. 369-375.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-15/'>Volume 15</a>, <a href='/categories/issue-4/'>Issue 4</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Screening%20for%20Familial%20Intracranial%20Aneurysms%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fscreening-for-familial-intracranial-aneurysms%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Screening%20for%20Familial%20Intracranial%20Aneurysms%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fscreening-for-familial-intracranial-aneurysms%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fscreening-for-familial-intracranial-aneurysms%2F&text=Screening%20for%20Familial%20Intracranial%20Aneurysms%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/abstracts-of-funded-national-institutes-of-health-grants/"><div class="card-body"> <em class="small" data-ts="1206982800" data-df="ll" > Mar 31, 2008 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Abstracts of Funded National Institutes of Health Grants</h3><div class="text-muted small"><p> The following abstracts of diagnostic radiology research and training grants funded by the National Institutes of Health (NIH) were awarded to principal investigators (PIs) whose primary appointmen...</p></div></div></a></div><div class="card"> <a href="/posts/breast-mri-for-cancer-detection-and-characterization/"><div class="card-body"> <em class="small" data-ts="1206982800" data-df="ll" > Mar 31, 2008 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Breast MRI for Cancer Detection and Characterization</h3><div class="text-muted small"><p> Rationale and Objectives Breast MRI is an important new tool in the imaging armamentarium for the detection and characterization of breast carcinoma. Understanding the evidence-supported benefits ...</p></div></div></a></div><div class="card"> <a href="/posts/communication-in-the-diagnostic-mammography-suite-implications-for-practice-and-training/"><div class="card-body"> <em class="small" data-ts="1206982800" data-df="ll" > Mar 31, 2008 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Communication in the Diagnostic Mammography Suite Implications for Practice and Training</h3><div class="text-muted small"><p> Rationale and Objectives The diagnostic mammography suite is a microcosm of challenging physician–patient communication in radiology. Little has been written about communication practices in the d...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/reimbursement-health-and-politics/" class="btn btn-outline-primary" prompt="Older"><p>Reimbursement, health, and politics</p></a> <a href="/posts/the-bookshelf/" class="btn btn-outline-primary" prompt="Newer"><p>The bookshelf</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
